Haemonetics Stock Price, News & Analysis (NYSE:HAE)

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HAE shares.
View HAE analyst ratings or view top-rated stocks.

4 analysts have issued twelve-month target prices for Haemonetics' stock. Their HAE share price targets range from $88.00 to $115.00. On average, they expect the company's stock price to reach $103.40 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price.
View analysts price targets for HAE or view top-rated stocks among Wall Street analysts.

Haemonetics' stock was trading at $78.65 at the beginning of the year. Since then, HAE shares have increased by 7.1% and is now trading at $84.26.
View the best growth stocks for 2023 here.

Haemonetics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,800,000 shares, an increase of 7.1% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 276,000 shares, the days-to-cover ratio is presently 6.5 days. Currently, 3.6% of the shares of the company are short sold.
View Haemonetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our HAE earnings forecast.

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Thursday, November, 2nd. The medical instruments supplier reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.05. The medical instruments supplier had revenue of $318.18 million for the quarter, compared to the consensus estimate of $319.18 million. Haemonetics had a net margin of 10.35% and a trailing twelve-month return on equity of 22.33%.

ETFs with the largest weight of Haemonetics (NYSE:HAE) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap Momentum ETF (XMMO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Health Care ETF (MEDI) and Cultivar ETF (CVAR).iShares Russell 2000 Growth ETF (IWO).

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Haemonetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (6.24%), FMR LLC (3.19%), Schroder Investment Management Group (1.52%), Boston Partners (1.44%), Boston Trust Walden Corp (1.42%) and Northern Trust Corp (1.26%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends.

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.